{"Clinical Trial ID": "NCT00149214", "Intervention": ["INTERVENTION 1:", "Pemetrexed Plus Doxorubicin, followed by Docetaxel", "Pemetrexed: 500 mg/m^2, intravenous (IV) every 21 days, 4 cycles (1-4) doxorubicin: 60 mg/m^2, intravenous (IV) every 21 days, 4 cycles (1-4) docetaxel: 100 mg/m^2, intravenous (IV) every 21 days, 4 cycles (5-8)", "INTERVENTION 2:", "- Cyclophosphamide Plus Doxorubicin, followed by Docetaxel", "Cyclophosphamide: 600 mg/m^2, intravenous (IV) every 21 days, 4 cycles (1-4) doxorubicin: 60 mg/m^2, intravenous (IV) every 21 days, 4 cycles (1-4) docetaxel: 100 mg/m^2, intravenous (IV) every 21 days, 4 cycles (5-8)"], "Eligibility": ["Incorporation criteria:", "A histologically confirmed diagnosis of primary early breast cancer, tumour size greater than or equal to 2 centimetres (cm), stages T2-T4/N0-2.", "Performance Status 0-2 Eastern Cooperative Oncology Group (ECOG).", "Adequate function of the organ (bone, liver, kidney, heart).", "- Exclusion criteria:", "- Previous anthracyclines as part of previous anticancer treatment.", "- Concomitant antitumour treatment.", "Second primary malignancy.", "- Serious concomitant systemic disorders.", "\u2022 Pre-existing sensory or motor neuropathy", "- Class 1."], "Results": ["Performance measures:", "Number of participants with a complete pathological response", "- Pathological evaluation of tissue removed during surgery to determine if tumour tissue is still present after chemotherapy", "Time limit: surgery after eight cycles of 21 days of chemotherapy", "Results 1:", "Title of the arm/group : Pemetrexed Plus Doxorubicin, followed by Docetaxel", "- Arm/group description: pemetrexed: 500 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4) doxorubicin: 60 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4) docetaxel: 100 mg/m^2, intravenous (IV), every 21 days, 4 cycles (5-8)", "Total number of participants analysed: 127", "Type of measurement: Number", "Unit of measure: participants Complete pathological response: 21", "Tumor cells are still present: 99", "Non-evaluable: 7", "Results 2:", "Title of the arm/group: Cyclophosphamide Plus Doxorubicin, followed by Docetaxel", "Description of the arm/group: cyclophosphamide: 600 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4) doxorubicin: 60 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4) docetaxel: 100 mg/m^2, intravenous (IV), every 21 days, 4 cycles (5-8)", "Total number of participants analysed: 119", "Type of measurement: Number", "Unit of measure: participants Complete pathological response: 24", "Tumor cells are still present: 89", "Non-evaluable: 6"], "Adverse Events": ["Undesirable Events 1:", "Total: 15/134 (11.19 per cent)", "Anemia 0/134 (0.00 %)", "Chronic lymphocyte leukaemia 0/134 (0.00 %)", "- Febrile neutropenia 4/134 (2.99%)", "Leukopenia 4/134 (2.99%)", "Neutropenia 1/134 (0.75%)", "Cardiovascular impairment 0/134 (0.00 %)", "Myocardial infarction 0/134 (0.00 %)", "Diarrhoea 1/134 (0.75%)", "Nausea 2/134 (1.49%)", "Stomatitis 1/134 (0.75%)", "Vomiting 3/134 (2.24 per cent)", "Adverse Events 2:", "Total: 25/123 (20.33 per cent)", "Anemia 1/123 (0.81%)", "Chronic lymphocyte leukaemia 1/123 (0.81%)", "5/123 (4.07 per cent)", "Leukopenia 9/123 (7.32%)", "Neutropenia 3/123 (2.44%)", "Cardiovascular impairment 1/123 (0.81%)", "Myocardial infarction 1/123 (0.81%)", "Diarrhoea 1/123 (0.81%)", "Nausea 0/123 (0.00 %)", "- Stomatitis 0/123 (0.00 %)", "Vomiting 0/123 (0.00 %)"]}